 LOS ANGELES--BUSINESS WIRE--WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. Nasdaq: LIXT, a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, with certain institutional and accredited investors for 4.19 million of common stock. The Company issued a total of 1,133,102 shares of common stock, at a 